← Disc Medicine, Inc. (IRON) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Disc Medicine, Inc. (IRON)
Pharmaceutical Preparations · market cap $2.5B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Disc Medicine (IRON) is a ~$2.9B market cap clinical-stage pharma focused on hematologic diseases, with a 142-person team and three active programs: DISC-1459 (Phase 3, erythropoietic protoporphyria), DISC-0974 (Phase 2, myelofibrosis-associated anemia), and DISC-3405 (Phase 2, polycythemia vera). The company's most critical near-term event is an estimated September 2026 Phase 3 readout for DISC-1459, arriving in the shadow of a June 2026 PDUFA that resulted in a negative outcome. Cash of $88.9M and a 4.3-month runway make this a high-urgency binary situation.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-05-15 (est.)Phase 2 · DISC-0974imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| DISC-0974 | Phase 2 | Myelofibrosis; Anemia |
| DISC-1459 | Phase 3 | Erythropoietic Protoporphyria |
| DISC-3405 | Phase 2 | Polycythemia Vera (PV) |
Price & technical context
3-month
-16.6%
6-month
-1.8%
12-month
-3.7%
52-wk range
$55.95–$94.11
vs 50-day MA
-15.3%
vs 200-day MA
-11.6%
Realized vol
53.9%
Max drawdown
-49.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IRON (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.